All In Biotech

Drug Trial Radar · NCT06821464

A Trial of HRS-9813 in Healthy Subjects

Safety, Tolerability and Pharmacokinetics of HRS-9813 After Multiple Oral Administration in Healthy Subjects-A Phase I Clinical Study

Last checked: Nov 20, 2026Latest source record: Jul 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

45

Actual

Start

Feb 17, 2025

Primary completion

Jul 27, 2025

Study completion Jul 27, 2025

Sponsor

Sponsor type
Industry
First posted
Feb 12, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The study is being conducted to evaluate the safety and pharmacokinetics of HRS-9813 after multiple oral administration in healthy subjects.

Conditions

  • Idiopathic Pulmonary Fibrosis/Progressive Pulmonary Fibrosis

Interventions

  • HRS-9813Drug

    Initial dose to planned dose(low dose)

  • HRS-9813Drug

    Initial dose to planned dose(high dose)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety outcomes: Incidence and severity of AEs.Time frame: Day -14 to Day 22

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai General Hospital

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.